Episode 910: Most Investors Miss This Biotech Error. Sellas SLS Short Thesis. Tenax Therapeutics

**Martin Shkreli** (0:00)
Yeah, we should look into it, that's a good idea. Learning biotech, if you don't have time to focus on it, it's kind of a weird question. HMAP is how you get the heat map. You have to learn all the mnemonics for Godel. MAP, really need to update this, so you can just add whatever stocks you want for your port. You know, right now, it just supports S&P 500, we're going to change that. Check, check, you guys can hear me okay? godelterminal.com, you can learn organic chem on the side. It might take you a couple of years, but you could definitely do it. Let's go Micron. I see Micron's back. Yeah, I ran into some colleagues, sorry. Okay, I trimmed some Micron.
I probably shouldn't have honestly, but I was a little oversized there. I have 25 bands on Micron. This EVMN is not Rocket Lab picked back up. No, I think we're ready to get back in the quantum short at the right time. Curious what Rocket Lab said for Q2. Yeah, I don't think so, ROCALC. 230, still really healthy revenue growth. Yeah, maybe stay away from Rocket Lab short. I don't know what the SPAC taken over by TOC- I don't know. Well, Micron 1100 again. Let's go short some Cerebrus against the Micron, but Cerebrus got a lot of momentum. Tenax. Yeah, let's look at Tenax. Tenax. Can Tenax Tenax? Yeah, it would be fun to do that. 26 million shares outstanding. Did they split or something? Reverse split. 118 in cash. Okay, still have preferred stock. Okay, converts to 45 million shares outstanding. Fully diluted. So it's not a small market cap, 600 cap here. Okay, they've refunded warrants.
Tenax 103 Top line results in Q3. So this is coming. No, I'm long Micron.
Wilmeri Hypertension with heart failure and Preserved Ejection Fraction. Car. When to sell Micron? Good question.
I guess we have a map now. I go down. Let me check that out. Map. This is all the live stock markets. It's kind of cool. So this is the window of live stock markets. Berlin is closing in like an hour. I can't zoom in. Oh, I can. Nice. London is post-market. You guys see this? Oh, can you see? Yeah. Italy, post-market, but Germany is still open. Let's go back to the US.
It's 25 markets open here. If we zoom in even further, can we click this? Oh, I thought they made it. They made a cool new thing where I could see that a little differently, but that's all right. Yeah. Just type map and hit enter on Godel. Wow, Eve of Mune is crushing me. All right. So Tenax, we can wait a little bit. It's not that urgent, but it is coming soon. It's going to be happy. Doesn't look good. It's all right. Dars looks amazing drug. Carbic D keeps growing. Maybe look one of my legend. Tech Veli is CD3 or vice specific with BCMA T cell. That's up to a billion and it competes with Carbic D. Yeah, Kaspersky, tell me about it. Telvae is also multiple myeloma, part of their massive armamentarium for ribavrant. Yes, they're combining that with Lazclues, both non-small cell EGFR drugs. Then you got good old Erleada, eventually gonna go generic. Imbruvica is just getting destroyed.
Lily's drug is superior to Imbruvica. I was surprised when I saw that. Just a better binder, I guess. They probably took some drugs out of oncology. Here, let's see what they take out. Zytiga probably, yeah. Ribavirant, 257 Okay, Tramphya is phya. Huge number, 16.08 mil, up 70% year over year. Unbelievable. Immunology, man. Almost a $10 billion drug. We're around $6 billion right now, but should settle in around $10 billion. Stellara Biosimilar now, 656 Rest in peace to Stellara. And Remicade's hanging in there at over a billion, despite biosimilars.
You know, not bad. Still blockbuster. No IP blockbusters. Gotta love it. Spravato, my ketamine drug. Doing fine. Keplida.
Man, I don't know about this deal they did for Keplida. In Vegas, Astana. Wow, still growing. No, flattish, but still impressive. J&J, man. Infectious disease franchise for J&J is basically gone now. A long time ago, they bought a company called TeboTech that kind of started this off, but now there's no more.
There really aren't any infectious diseases left to treat. Maybe have B. Keplida to the CNS section. Oh yeah, I got to call this guy. Might have to hop.
I've been talking about SLS all day. Did you just get here? Uh...
SLS is zero. I mean, if you think that drug works, you need your brain checked or you're brand new to pharma, which, you know, you'll learn something. It's good to learn. Oh, the patient's still alive! Man, I wish you guys were around when Uncle Thyreon had this situation. This happens in biotech practically every year. There's some trial that's taking longer than expected, and the immediate thought is, oh my god, they must be living longer! Poor guys, you're going to learn something. You could hire a statistician to help you. Almost always, the company is just over. Just make the wrong assumption, basically, on how much the baseline will do. Pretty basic error. Yeah, it just is what it is, man. You'll see. But yeah, man, make the bet, you know? If you believe in, you know, you know for sure how many years the... This just happened with, you know, what I shorted that were sort of the same thing, was, what was that stupid company with the polokinase inhibitor? Who had that polokinase? This was the same situation. Everybody thought, oh my god, you know, they must be doing so well. And it was still Cardiff, CRDFF, CRDF. Yeah, the same story with Cardiff, you know, but that did not go so great. There's the chart of Cardiff, as people were looking at the historical survival for, what were they, were they colon? Or were they lung? I forget. I think they were colon. And geniuses who were brand new to biopharma said, well, they must be doing really well, because the literature says they only lived to eight months, so they must be living 24 months. No, look, I mean, I need to take your money, so I want you to be long. I don't know, I'm not trying to convince you of anything. I need your cash, I don't want you to stay in, buy more. Okay, Micron's 11, 11, 11.5.